IXC - Invex TherapeuticsThis company is a Phase 3 ORPHAN bio focusing in on IIH.
They have 31 mill cash on hand which will fully fund them all the way. They are currently valued at 40 mill MC so essentially 9 mill EV which is ridiculous for a Phase 3 bio.
Putting in a bottoming pattern now with a reverse head and shoulders developing.
A break of 80 cents will be the trigger point, at the moment its just in accumulation phase still
IXC trade ideas
$IXC - INVEX THERAPEUTICS - New ASX listingInvex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke.
It only just listed but seems to be headed the right way price wise. It is already up another 16% today with 99 buyers for 659,825 units vs 30 sellers for 233,020 units. Pity I didn't see it sooner.
Looks good on the 15 min chart. Might be worth a watch.
Invex Therapeutics Ltd (IXC) is a biopharmaceutical company, focused on the research and development of Exenatide as an efficacious treatment for neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke, hydrocephalus, venous sinus thrombosis, brain tumours, meningitis, secondary pseudo tumour cerebri and traumatic brain injury.
INVEX TH$IXC $IXC.AX - breaking above resistance - LONGInvex Therapeutics aims to re-purpose a diabetic drug for brain disorders such as idiopathic intracranial hypertension, traumatic brain injury and acute stroke. As the product is already in production and use there is an easy route to entry.
Sector: Healthcare
Industry: Pharmaceuticals
Supply is being soaked and the price has been slowly appreciating due to accumulation.
BioTech sector with Top 20 holding 80%
Market Cap $44m
Cash Rich (Circa $10m)
IPO at 0.40
Quality Management
Price reversal upwardly trending price